AIT Therapeutics Announces Publication of Its Phase 2 Trial in Bronchiolitis Patients in the Pediatric Pulmonology Journal

NEW YORK, AITB, (GLOBE NEWSWIRE) AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced publication of its Phase 2, double-blind, randomized controlled trial for treatment of infants with moderately severe bronchiolitis.  The article, entitled Nitric Oxide Inhalations in Bronchiolitis: A Pilot, Randomized, Double-Blinded, Controlled Trial was published in the December 2017 issue of the peer-reviewed Pediatric Pulmonology journal. “We are pleased to see
http://bit.ly/2BAMcmU